Spyre Therapeutics, Inc. (SYRE) stock
SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$93.81−5.56 (-5.60%)
Close on Nov 17, 2026Market cap $8.27BP/E –Yield –
Spyre Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Spyre Therapeutics's ebitda for the twelve months ending Dec 31, 2024 was -$208.57M. For fiscal 2025 it was -$209.56M. The highest annual figure on record is -$8.89M in fiscal 2014.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$209.56M | – |
| FY2024 | Dec 31, 2024 | -$208.57M | – |
| FY2023 | Dec 31, 2023 | -$241.56M | – |
| FY2022 | Dec 31, 2022 | -$83.21M | – |
| FY2021 | Dec 31, 2021 | -$64.07M | – |
| FY2020 | Dec 31, 2020 | -$80.49M | – |
| FY2019 | Dec 31, 2019 | -$79.92M | – |
| FY2018 | Dec 31, 2018 | -$45.17M | – |
| FY2017 | Dec 31, 2017 | -$27.43M | – |
| FY2016 | Dec 31, 2016 | -$21.77M | – |
| FY2015 | Dec 31, 2015 | -$11.23M | – |
| FY2014 | Dec 31, 2014 | -$8.89M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | -$61.25M | – |
| Q3 FY2024 | Sep 30, 2024 | -$55.39M | – |
| Q2 FY2024 | Jun 30, 2024 | -$44.15M | – |
| Q1 FY2024 | Mar 31, 2024 | -$47.77M | – |
| Q4 FY2023 | Dec 31, 2023 | -$45.91M | – |
| Q3 FY2023 | Sep 30, 2023 | -$18.34M | – |
| Q2 FY2023 | Jun 30, 2023 | -$158.89M | – |
| Q1 FY2023 | Mar 31, 2023 | -$18.42M | – |
| Q4 FY2022 | Dec 31, 2022 | -$18.78M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.35M | – |
| Q2 FY2022 | Jun 30, 2022 | -$22.05M | – |
| Q1 FY2022 | Mar 31, 2022 | -$24.04M | – |
| Q4 FY2021 | Dec 31, 2021 | -$20.03M | – |
| Q3 FY2021 | Sep 30, 2021 | -$19.88M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.31M | – |
| Q1 FY2021 | Mar 31, 2021 | -$17.85M | – |
| Q4 FY2020 | Dec 31, 2020 | -$22.41M | – |
| Q3 FY2020 | Sep 30, 2020 | -$17.87M | – |
| Q2 FY2020 | Jun 30, 2020 | -$21.34M | – |
| Q1 FY2020 | Mar 31, 2020 | -$18.87M | – |
| Q4 FY2019 | Dec 31, 2019 | -$21.80M | – |
| Q3 FY2019 | Sep 30, 2019 | -$22.04M | – |
| Q2 FY2019 | Jun 30, 2019 | -$18.52M | – |
| Q1 FY2019 | Mar 31, 2019 | -$17.56M | – |
| Q4 FY2018 | Dec 31, 2018 | -$15.23M | – |
| Q3 FY2018 | Sep 30, 2018 | -$12.17M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.60M | – |
| Q1 FY2018 | Mar 31, 2018 | -$8.18M | – |
| Q4 FY2017 | Dec 31, 2017 | -$6.56M | – |
| Q3 FY2017 | Sep 30, 2017 | -$7.93M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.66M | – |
| Q1 FY2017 | Mar 31, 2017 | -$6.28M | – |
| Q4 FY2016 | Dec 31, 2016 | -$5.51M | – |
| Q3 FY2016 | Sep 30, 2016 | -$6.27M | – |
See a number that looks wrong?